About 7,000 people work at Biogen worldwide, according to its LinkedIn page, meaning it plans to reduce its workforce by more than than 10 percent.
The biotech recently secured full approval for Leqembi, an Alzheimer’s drug label it shares with Japan-based Eisai. It plans to launch the drug by the end of 2023.
The company has not submitted a WARN notice in Massachusetts, according to the state’s records, which were last updated July 21.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
